MassDevice asks the CEOs of Zoll Medical, Semprus Biosciences, IlluminOss Medical and Good Start Genetics what keeps them up at night at the 2011 MassDevice.com Big 100 Roundtable East.
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This latest feature of MassDevice.com’s coverage highlights our three biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you’re still in the know with Massdevice +3.
Med-tech leaders came together for a meeting of the minds at MassDevice’s first Big 100 Regional Roundtable in Waltham, Mass., July 11. Four CEOs, each representing an interesting and important sector of the life science industry – the fascinating juncture between orthopedics and minimally invasive techniques, genomics and personalized medicine, the cutting edge of bio-interactive nanotech coatings and the mid-cap medical device world – shared their thoughts on the particular challenges facing their businesses and the life sciences industry as a whole.
FDA CDRH chief Dr. Jeffrey Shuren addresses the
audience in a live Q&A
Hundreds of representatives from New England’s medical device industry gathered last night at the MassDevice Big 100 Regional Roundtable at the Westin Hotel in Waltham, Mass., to share their experiences and ideas for the industry’s future.
Good Start Genetics Inc., which earlier this month raised $18 million in venture financing, has repaid its debt to the Commonwealth in full, or at least until next tax season.
The Boston-based company, which is developing a pre-pregnancy genetic test designed to screen for a panel of genetic disorders, won a $500,000 “accelerator” loan from the Massachusetts Life Sciences Center in April 2009. It’s the first of the seven companies to receive the state’s assistance to pay off its loan.
Good Start Genetics Inc. closed an $18 million Series A funding round and tapped former Exact Sciences Corp. (NSDQ:EXAS) head Don Hardison to be its president and CEO.
The Boston-based company is developing a pre-pregnancy genetic test designed to screen for a panel of genetic disorders, including sickle-cell anemia and cystic fibrosis. Hardison told MassDevice that Good Start will use the financing to commercialize the test, which he expects to hit the market some time next year.